Zacks Research Has Bullish Forecast for BMRN Q4 Earnings

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) – Equities researchers at Zacks Research upped their Q4 2025 earnings per share (EPS) estimates for BioMarin Pharmaceutical in a note issued to investors on Monday, February 17th. Zacks Research analyst S. Ganoria now forecasts that the biotechnology company will post earnings of $0.67 per share for the quarter, up from their previous estimate of $0.66. The consensus estimate for BioMarin Pharmaceutical’s current full-year earnings is $2.50 per share. Zacks Research also issued estimates for BioMarin Pharmaceutical’s Q1 2026 earnings at $0.78 EPS.

BioMarin Pharmaceutical (NASDAQ:BMRN) last announced its quarterly earnings data on Wednesday, February 19th. The biotechnology company reported $0.72 EPS for the quarter, beating the consensus estimate of $0.54 by $0.18. BioMarin Pharmaceutical had a return on equity of 8.53% and a net margin of 11.71%.

BMRN has been the topic of several other reports. Citigroup lowered their price objective on BioMarin Pharmaceutical from $93.00 to $81.00 and set a “neutral” rating on the stock in a research report on Wednesday, October 30th. Evercore ISI reduced their target price on BioMarin Pharmaceutical from $115.00 to $105.00 and set an “outperform” rating on the stock in a report on Wednesday, October 30th. Robert W. Baird reduced their target price on BioMarin Pharmaceutical from $72.00 to $65.00 and set a “neutral” rating on the stock in a report on Wednesday, October 30th. JPMorgan Chase & Co. reduced their target price on BioMarin Pharmaceutical from $110.00 to $109.00 and set an “overweight” rating on the stock in a report on Wednesday, October 30th. Finally, StockNews.com raised BioMarin Pharmaceutical from a “buy” rating to a “strong-buy” rating in a report on Tuesday, February 11th. Seven investment analysts have rated the stock with a hold rating, fifteen have given a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, BioMarin Pharmaceutical presently has an average rating of “Moderate Buy” and an average target price of $94.20.

BioMarin Pharmaceutical Price Performance

Shares of BioMarin Pharmaceutical stock opened at $65.61 on Wednesday. The stock’s 50-day simple moving average is $64.79 and its 200-day simple moving average is $71.10. BioMarin Pharmaceutical has a 52 week low of $60.63 and a 52 week high of $94.85. The company has a market capitalization of $12.50 billion, a price-to-earnings ratio of 39.29, a PEG ratio of 0.57 and a beta of 0.28. The company has a quick ratio of 2.62, a current ratio of 4.27 and a debt-to-equity ratio of 0.11.

Institutional Trading of BioMarin Pharmaceutical

Large investors have recently modified their holdings of the company. Merit Financial Group LLC purchased a new stake in shares of BioMarin Pharmaceutical in the fourth quarter valued at approximately $317,000. Assenagon Asset Management S.A. boosted its holdings in shares of BioMarin Pharmaceutical by 461.3% in the fourth quarter. Assenagon Asset Management S.A. now owns 611,667 shares of the biotechnology company’s stock valued at $40,205,000 after purchasing an additional 502,695 shares during the period. Wedmont Private Capital purchased a new stake in shares of BioMarin Pharmaceutical in the fourth quarter valued at approximately $430,000. Swedbank AB boosted its holdings in shares of BioMarin Pharmaceutical by 11.2% in the fourth quarter. Swedbank AB now owns 432,122 shares of the biotechnology company’s stock valued at $28,403,000 after purchasing an additional 43,593 shares during the period. Finally, EULAV Asset Management boosted its holdings in shares of BioMarin Pharmaceutical by 12.9% in the third quarter. EULAV Asset Management now owns 131,000 shares of the biotechnology company’s stock valued at $9,208,000 after purchasing an additional 15,000 shares during the period. Hedge funds and other institutional investors own 98.71% of the company’s stock.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.